

Transforming patients' lives through science™



## Our Mission

To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

## Our Vision

To be the leading pharmaceutical company in Switzerland that transforms patients' lives through science.

## Bristol Myers Squibb in Switzerland


**1,220** employees at five different locations, including three production facilities, make us one of the top five pharmaceutical companies in Switzerland.

**Boudry**  
Pharmaceutical company and global functions  
830 employees including apprentices

**Couvet**  
Production facility  
110 employees including apprentices

**Steinhausen**  
Swiss branch, CHAT functions & Global Capabilities Hub  
213 employees

**Zurich**  
Swiss branch & CHAT functions  
40 employees



**Professionals incl.:**  
Administration  
Biostatisticians  
Chemists  
Pharmacists  
Physicians

**Functions:**  
Corporate Affairs  
Drug Safety  
Finance  
Human Resources  
Information Technology  
Legal & Compliance  
Manufacturing  
Market Access & Gov. Affairs  
Marketing  
Medical Affairs  
Quality Assurance  
Regulatory  
Supply Chain  
Strategy & Operations



99% of finished goods produced in Boudry and Couvet are exported to 80 countries.



We drive collaborative and constructive partnerships and open dialogue among stakeholders to create a healthcare system that provides patients with innovative medicines in a sustainable way.



Our ambition is to be one of the best employers in Switzerland. Ranking 4<sup>th</sup> in the "Great Place To Work" survey proves that we are taking this seriously.



## Research and Development

We are the leader in conducting clinical trials in Switzerland, ensuring patients get early access to innovative medicines in the fight against cancer, the second leading cause of mortality.

We have one of the most diverse and promising pipelines in the industry fueled by research in oncology, hematology, immunology, and cardiovascular diseases.

**60** clinical studies together with Cantonal and University Hospitals in Switzerland in 2020\*

**50+** Investigational therapies globally in the areas of:

|                       |                          |
|-----------------------|--------------------------|
| <b>Oncology</b>       | <b>Immunology</b>        |
| <b>Hematology</b>     | <b>Fibrotic Diseases</b> |
| <b>Cardiovascular</b> | <b>Neuroscience</b>      |

| Leading Franchises                 | Deep and Broad Late-Stage Pipeline                      | Robust Early-Stage Pipeline Phase I/II Assets |
|------------------------------------|---|---|
| <b>#1</b><br>Oncology & Hematology | <b>8</b><br>Near-term potential launches                | <b>19</b><br>Oncology                         |
| <b>#1</b><br>Cardiovascular        | <b>9</b><br>Phase III assets                            | <b>15</b><br>Hematology                       |
| Growing Immunology Franchise       | <b>20+</b><br>Life cycle management opportunities in IO | <b>5</b><br>Cardiovascular                    |
|                                    |   | <b>9</b><br>Immunology                        |
|                                    |   | <b>5</b><br>Fibrosis                          |

\* as of 09/23/2020; source: clinicaltrials.gov